📰 Pfizer Ventures News
Page 2 - Pfizer Ventures News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pfizer Ventures. Real-time updates on events, politics, business and more.
February 27, 2024
Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline
December 11, 2023
HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptorDesigned to target myeloid, NK and T cells and to be precisely directed to t...
December 8, 2023
/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting...
December 6, 2023
BOSTON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that
November 16, 2023
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
November 14, 2023
Total Deal Value of Up to $770.5 million including Upfront Payment and Potential Milestone Payments Autifony Eligible to Receive Royalties on Future Net Sales ...
October 24, 2023
Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress 2023 (Madrid, Spain)Dose
October 19, 2023
17 Oct 2023 STORMs first-in-class investigational drug STC-15 is the first clinical stage molecule specifically targeting an RNA methyltransferase ...
October 17, 2023
/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA...
October 17, 2023
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors